<DOC>
	<DOCNO>NCT02289300</DOCNO>
	<brief_summary>The purpose study determine whether investigational drug DCB-BO1202 effective safe treatment liver fibrosis HBV patient experience intermediate stage hepatocellular carcinoma ( HCC )</brief_summary>
	<brief_title>A Study Evaluate Study Drug , DCB-BO1202 , Alleviating Liver Fibrosis Liver Cancer Patients</brief_title>
	<detailed_description>The study include first 188 subject randomize . The purpose study collect efficacy result evaluate treatment effect primary endpoint . The second endpoint evaluate drug safety incidence primary endpoint treatment period .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>1 . Aged 2065 year ( inclusive ) either gender 2 . With evidence HBV infection confirm positive Hepatitis B virus antigen ( HBsAg ) 3 . With Barcelona Clinic Liver Cancer ( BCLC ) intermediate stage ( BCLCB ) hepatocellular carcinoma ( HCC ) 4 . Having receive radiofrequency ablation ( RFA ) transarterial embolization ( TAE ) hepatitis B virus ( HBV ) relate hepatocellular carcinoma least 4 week Screening 5 . With liver stiffness measurement ( assessed Fibroscan® ) 720 kPa 6 . Able understand willing sign inform consent 1 . Evidence history chronic hepatitis cause Hepatitis C virus ( HCV ) 2 . With abnormal organ function absolute neutrophil count ( ANC ) &lt; 1500 /μL , hemoglobin &lt; 9 gm/dL , platelet &lt; 50,000 /μL , creatinine &gt; 2 mg/dL , alanine aminotransferase ( AST ) ALT &gt; 5 X upper normal limit current institution ; bilirubin &gt; 2.5 mg/dL , prothrombin time ( PT ) prolongation &gt; 4 sec upper limit normal 3 . With uncontrolled infection serious infection within past 4 week 4 . With carcinoma except skin cancer 5 . Women pregnant breastfeed childbearing potential unable unwilling practice highly effective mean contraception 6 . Active substance abuse , include alcohol , , opinion investigator , risk impair ability patient comply protocol 7 . History allergy substance investigational product 8 . With known human immunodeficiency virus ( HIV ) infection 9 . Judged applicable study investigator difficulty followup observation 10 . With serious diseases/medical history consider investigator condition enter trial 11 . Administered antiHBV drug within 4 week enter study . ( Note : AntiHBV treatment allow take study period necessary . ) 12 . Having participate investigational study within 4 week enter study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>